Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio.

Dermavant Sciences has shared positive long-term results for its plaque psoriasis-approved Vtama (tapinarof) cream in adults and children as young as two years old with atopic dermatitis (AD).

FDA PDUFA Action Date for Topical Treatment of Atopic Dermatitis with VTAMA cream is Expected in Q4 2024. LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a ...

“The future of dermatology depends on innovative treatments like VTAMA, and Organon’s acquisition of Dermavant allows us to further expand our existing portfolio of established brands and ...

VTAMA ® (tapinarof) cream, 1%, is a novel nonbiologic, non-steroidal topical therapy approved by the U.S. Food and Drug Administration (FDA) for treatment of mild, moderate, and severe plaque ...

With the deal's closure, Organon has added Dermavant’s VTAMA (tapinarof) cream 1%, a US Food and Drug Administration (FDA)-approved nonbiologic, non-steroidal topical treatment, to its portfolio.

The data presented were generated from Dermavant’s Phase 3 ADORING 1 and ADORING 2 pivotal trials studying VTAMA cream, 1% in patients with moderate to severe atopic dermatitis as young as two ...

The recent acquisition of Dermavant, which brought VTAMA into Organon's portfolio, has been viewed as a strategic move to broaden the company's dermatology offerings in the U.S. market.

Analysts project VTAMA's sales potential to reach $500 million or more, contingent upon successful pediatric market penetration and patients switching from topical steroids. The recent acquisition of ...